BioAlliance Pharma inked a licensing agreement with Innocutis Holding to commercialize Sitavig® (acyclovir Lauriad®) for the treatment of recurrent labial herpes in North America. The company is eligible to receive a total of $5 million in upfront and milestone payments. The agreement also includes double-digit royalties.

In addition, BioAlliance received a positive opinion from the Health Authorities in France and Germany for the Market Authorization of the drug. Sitavig had already been registered in eight European countries through a decentralized procedure in December 2012. As its registration strategy, the company had filed in these countries first to ensure optimized registration timelines, and then filed a mutual recognition procedure in France and Germany.

“We are delighted with this agreement with Innocutis, a strategic U.S. partner with a highly skilled management team and a dedicated sales force, and we trust this collaboration will ensure the rapid and successful commercialization of Sitavig® in the U.S., the largest sales potential market, estimated up to $500M,” commented Judith Greciet, CEO of BioAlliance Pharma. “In Europe, regulatory procedure has been finalized with success and Sitavig® is now approved in all key countries. Indeed, we are confident that it will significantly help licensing discussions with potential European partners, already fairly well advanced.”

Previous articleDr. Falk Scores Rights to Medigene’s RhuDex for Hepatological, Gastroenterological Indications
Next articleSanofi, SK to Co-Develop Pneumococcal Conjugate Vaccine